Santersus AG Completes Series A Financing and Announces Strategic Collaboration with Terumo Corporation

About this update from Terumo Corporation

[{"type":"text","content":"Santersus AG Announces Advancement of NucleoCapture into Pivotal Clinical Development strengthened by Strategic Collaboration with Terumo","length":137,"tagName":"p"},{"type":"text","content":"ZURICH, SWITZERLAND / ACCESS Newswire / December 1, 2025 / Santersus AG today announced the successful completion of its Series A financing, led by Norcliffe, a UK life sciences fund with participation from Terumo Ventures. The financing will support the advancement of Santersus' NucleoCapture into pivotal clinical development while accelerating progress across Santersus' broader pipeline.","length":400,"tagName":"p"},{"type":"text","content":"Santersus has entered a strategic collaboration with Terumo Blood and Cell Technologies to advance NucleoCapture(TM) for the treatment of sepsis, a disease that kills 11M people worldwide each year. The collaboration integrates Santersus' first-in-class NucleoCapture blood purification device with Terumo BCT's industry-leading Spectra Optia Apheresis System, creating a novel therapeutic apheresis approach designed to selectively remove neutrophil extracellular traps (NETs)- a major contributor to systemic inflammation and sepsis-related organ dysfunction. NucleoCapture has previously been granted two U.S. FDA Breakthrough Device Designations, including one for the treatment of sepsis.","length":701,"tagName":"p"},{"type":"text","content":"Under this collaboration, Santersus will lead the pivotal NUC-CAP clinical trial across the United States, United Kingdom, Switzerland and Europe. Terumo BCT will support the clinical development of the program, and Terumo Ventures - the corporate VC arm of Terumo - has invested in Santersus' Series A financing round to accelerate the development of this technology for a critical unmet need with high mortality.","length":418,"tagName":"p"},{"type":"text","content":""Therapeutic apheresis has untapped potential to address serious unmet medical needs," said Veerle d'Haenens, General Manager of Global Therapy Innovations at Terumo Blood and Cell Technologies. "Our partnership with Santersus reflects our commitment to advancing innovative treatment options for critically ill patients."","length":346,"tagName":"p"},{"type":"text","content":"The Series A financing will also support Santersus' preparation for pivotal clinical...

More updates from Terumo Corporation